These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 10946875

  • 1. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
    Finne P, Auvinen A, Koistinen H, Zhang WM, Määttänen L, Rannikko S, Tammela T, Seppälä M, Hakama M, Stenman UH.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2744-7. PubMed ID: 10946875
    [Abstract] [Full Text] [Related]

  • 2. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J, Diamandi A, Mistry J, Scorilas A.
    J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
    [Abstract] [Full Text] [Related]

  • 3. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
    Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF, Hsing AW.
    Cancer Epidemiol Biomarkers Prev; 2001 May 01; 10(5):421-7. PubMed ID: 11352850
    [Abstract] [Full Text] [Related]

  • 5. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar 01; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 6. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
    Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E.
    Cancer Causes Control; 2005 Apr 01; 16(3):255-62. PubMed ID: 15947877
    [Abstract] [Full Text] [Related]

  • 7. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug 01; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 8. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F.
    Urol Int; 2004 Aug 01; 72(1):62-5. PubMed ID: 14730168
    [Abstract] [Full Text] [Related]

  • 9. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK, Trachtenberg J, Jewett MA, Toi A, Evans A, Emami M, Narod SA, Pollak M.
    Cancer Epidemiol Biomarkers Prev; 2005 May 01; 14(5):1270-3. PubMed ID: 15894684
    [Abstract] [Full Text] [Related]

  • 10. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, Schröder FH.
    J Clin Endocrinol Metab; 2004 Sep 01; 89(9):4391-6. PubMed ID: 15356036
    [Abstract] [Full Text] [Related]

  • 11. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D.
    Cancer Res; 2003 Jul 15; 63(14):3991-4. PubMed ID: 12873996
    [Abstract] [Full Text] [Related]

  • 12. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG.
    Cancer Epidemiol Biomarkers Prev; 2006 Jun 15; 15(6):1137-41. PubMed ID: 16775172
    [Abstract] [Full Text] [Related]

  • 13. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z, Jieming L, Su L, Wenlu S.
    J Surg Oncol; 2007 Jul 01; 96(1):54-61. PubMed ID: 17345593
    [Abstract] [Full Text] [Related]

  • 14. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb 01; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 15. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection.
    Stattin P, Stenman UH, Riboli E, Hallmans G, Kaaks R.
    J Clin Endocrinol Metab; 2001 Dec 01; 86(12):5745-8. PubMed ID: 11739433
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
    Correa LL, Neto LV, Lima GA, Gabrich R, Miranda LC, Gadelha MR.
    Int Braz J Urol; 2015 Dec 01; 41(1):110-5. PubMed ID: 25928516
    [Abstract] [Full Text] [Related]

  • 17. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
    Povelitsa EA, Nabyrov EA.
    Vopr Onkol; 2008 Dec 01; 54(5):596-601. PubMed ID: 19069473
    [Abstract] [Full Text] [Related]

  • 18. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
    Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V, Di Silverio F.
    Urol Int; 2008 Dec 01; 80(1):68-73. PubMed ID: 18204237
    [Abstract] [Full Text] [Related]

  • 19. Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?
    Wolk A, Andersson SO, Mantzoros CS, Trichopoulos D, Adami HO.
    Lancet; 2000 Dec 02; 356(9245):1902-3. PubMed ID: 11130391
    [Abstract] [Full Text] [Related]

  • 20. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK, Han BK, Jeong JS, Jeong SJ, Moon KH, Byun SS, Lee SE.
    Asian J Androl; 2008 Mar 02; 10(2):207-13. PubMed ID: 18097534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.